BHVN vs NKTR vs INCY vs PFE

For growth investors, Incyte Corporation (INCY) is the stronger pick with 21.

2% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Incyte Corporation (INCY) offers the better valuation at 15. 3x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Biohaven Ltd. (BHVN) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.

3x versus Pfizer Inc. at 19. 5x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Biohaven Ltd.

(BHVN) delivered a total return of +33. 4%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: INCY returned +34. 2% versus NKTR's -59. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 54β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 240% more volatile than PFE relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 5% for Biohaven Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Incyte Corporation (INCY) is pulling ahead at 21.

2% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, INCY leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Incyte Corporation (INCY) is the more profitable company, earning 25.

0% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 25. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INCY leads at 26. 1% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 9x forward P/E versus 13. 1x for Incyte Corporation — 4. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BHVN: 118. 7% to $21. 29.

In this comparison, PFE (6.

5% yield) pays a dividend. BHVN, NKTR, INCY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFE: +29. 6%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BHVN is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; INCY is a mid-cap high-growth stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while BHVN, NKTR, INCY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.